CKLSF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.6 Med: 1.24 Max: 2.08
Current: 1.26
During the past 13 years, CK Life Sciences International Holdings's highest Cyclically Adjusted PB Ratio was 2.08. The lowest was 0.60. And the median was 1.24.
CKLSF's Cyclically Adjusted PB Ratio is ranked better than 57.37% of 699
companies
in the Biotechnology industry
Industry Median: 1.66
vs CKLSF: 1.26
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
CK Life Sciences International Holdings's adjusted book value per share data of for the fiscal year that ended in Dec25 was $0.051. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.04 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
CK Life Sciences International Holdings (OTCPK:CKLSF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
CK Life Sciences International Holdings Cyclically Adjusted PB Ratio Related Terms
CK Life Sciences International Holdings Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Cyclically Adjusted PB Ratio Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's Cyclically Adjusted PB Ratio falls into.
CK Life Sciences International Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.25 mean?
CK Life Sciences International Holdings (CKLSF) has a Cyclically Adjusted PB Ratio of 2.25 as of Jul. 08, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on CK Life Sciences International Holdings and its competitors. This is 81% above median its historical median of 1.24. Over the past decade, CK Life Sciences International Holdings' Cyclically Adjusted PB Ratio has ranged from 0.60 to 2.08. According to the industry distribution chart, CK Life Sciences International Holdings ranks #298 out of 699 companies in the Biotechnology industry, placing it in the top 42.6%.
Is CK Life Sciences International Holdings' Cyclically Adjusted PB Ratio too high?
CK Life Sciences International Holdings' current Cyclically Adjusted PB Ratio of 2.25 is 81% above median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 2.08. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.66. CK Life Sciences International Holdings' value of 2.25 is 35.5% above this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #298 out of 699 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #298 out of 699 companies for Cyclically Adjusted PB Ratio. This puts CK Life Sciences International Holdings in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.66. CK Life Sciences International Holdings' value of 2.25 is 35.5% above this benchmark. Historically, CK Life Sciences International Holdings' own Cyclically Adjusted PB Ratio has ranged from 0.60 to 2.08 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 1.66, CK Life Sciences International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.66, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Cyclically Adjusted PB Ratio of 2.25 is 35.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Cyclically Adjusted PB Ratio is 2.25, which is 81% above median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Cyclically Adjusted PB Ratio of 2.25. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.25, which is 81% above median its 10-year median of 1.24 and 35.5% above the Biotechnology industry median of 1.66. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Cyclically Adjusted PB Ratio is 2.25 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
Cyclically Adjusted PB Ratio: 2.25 (81% above median its 10-year median of 1.24)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
Industry Position: 35.5% above the Biotechnology median (#298 of 699)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
